OnKure Therapeutics, Inc.

What they do

OnKure uses structure-based drug design to develop small molecule inhibitors that selectively target mutated PI3Kα while sparing the wild-type enzyme, aiming to limit class toxicities such as hyperglycemia, GI effects, fatigue, and rash. Its lead candidate OKI-219, a PI3Kα H1047R inhibitor with roughly 80-fold selectivity over wild-type PI3K, is in the Phase 1 PIKture-01 trial in breast cancer and other solid tumors. The company also has next-generation pan-mutant candidates OKI-345 (breast cancer) and OKI-355 (vascular anomalies) in IND-enabling work.

Revenue drivers

• Product sales — None; OnKure has no approved products, has never generated revenue, and does not expect commercial revenue for the foreseeable future, if ever.
• OKI-219 (PI3Kα H1047R) — Lead clinical asset in Phase 1 PIKture-01; no revenue contribution, value contingent on clinical progress and eventual approval.
• OKI-345 (PI3Kα pan-mutant, breast cancer) — Preclinical next-generation candidate selected March 2026; IND submission planned for 1H 2027, no revenue.
• OKI-355 (PI3Kα pan-mutant, vascular anomalies) — Preclinical candidate announced March 2026, heading the vascular anomalies pipeline; IND planned for 1H 2027, no revenue.

Recent performance

OnKure reported a net loss of $30.5 million for the six months ended June 30, 2026, versus a full-year 2025 net loss of $59.5 million. R&D expenses were $12.6 million in Q2 2026, flat versus Q2 2025, as increased clinical trial and outsourced manufacturing spend was offset by lower outsourced preclinical R&D. As of June 30, 2026, the company held $176.4 million in cash, cash equivalents and marketable securities against an accumulated deficit of $244.7 million. Annual losses have widened from $35.3 million in 2023 to $52.7 million in 2024 and $59.5 million in 2025.

Strategy

The company has shifted its pipeline toward next-generation PI3Kα pan-mutant selective inhibitors, positioning OKI-355 in vascular anomalies and OKI-345 in breast cancer as its lead forward programs. It plans IND submissions for both candidates to the FDA in the first half of 2027 and has initiated a discovery program to expand the vascular anomalies pipeline beyond PI3Kα. OKI-219 remains in Phase 1 PIKture-01, with Parts A and B fully enrolled and Parts C (trastuzumab plus tucatinib) and E (fulvestrant plus ribociclib) enrolling. Management is funding operations with existing cash and has not guided to product revenue.

Risks

• No approved products or revenue — The company has never generated revenue and has not demonstrated ability to obtain marketing approvals, manufacture at commercial scale, or conduct sales and marketing.
• Early clinical and preclinical stage — OKI-219 is first-in-human and OKI-345/OKI-355 are preclinical, so safety, efficacy, and regulatory success remain unproven.
• Cash burn and funding need — OnKure used $51.8 million in operating cash flow in 2025, and continued expansion of trials and IND-enabling work may require additional capital despite a stated runway into 2029.
• Pipeline concentration in PI3Kα — All disclosed candidates target mutant PI3Kα, so shared biology, competition, or class-limiting toxicity could affect the entire portfolio.

Outlook

Management says IND submissions for OKI-345 and OKI-355 are on track for the first half of 2027 and describes $176 million in cash as sufficient to fund operations into 2029. It points to a recent Key Opinion Leader event and ISSVA World Congress participation as supporting the scientific rationale for pan-mutant selective inhibitors. Enrollment continues in PIKture-01 Parts C and E. No product revenue is expected for the foreseeable future.